Paris

• An Open-Label, Single-Arm, 3-Year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Subjects with Stargardt Disease Pending
  2025-522460-33-00 5 Stargardt Disease
• A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (P … Pending
  2025-522471-28-00 5 psoriatic arthritis (PsA)
• Sustained-release oral morphine to alleviate persistent dyspnea in patients with chronic respiratory insufficiency due to amyotrophic latera … Pending
  2025-522546-52-00 5 patients with chronic respiratory insufficiency due to amyotrophic lat
• A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination with Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compare … Pending
  2025-522563-15-00 10 Metastatic Pancreatic Ductal Adenocarcinoma; PDAC
• Usnoflast Neuromuscular Investigation for Treatment Efficacy in ALS (UNITE-ALS) Pending
  2025-522580-15-00 4 Amyotrophic Lateral Sclerosis (ALS)
• Proof-of-Concept Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of Intranasal Cenegermin in Adult Participants … Pending
  2025-522692-29-00 4 Subacute Moderate to Severe Traumatic Brain Injury (TBI)
• A Phase 1/2 Study of Inhaled KB707 in Patients Pending
  2025-522723-98-00 9 solid tumor
• Trial assessing treatment in patients with advanced Lung Cancer and Interstitial Lung Disease Pending
  2025-522790-10-00 4 Non Small Cell Lung Cancer
• Personnalized immunotherapy in patients with stage III non-small cell lung cancer Pending
  2025-522801-39-00 4 Stage III Non Small Cell Lung Cancer
• A Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell L … Pending
  2025-522818-23-00 5 Small Cell Lung Cancer (SCLC)
• Intermediate versus standard dose enoxaparin to prevent venous thromboembolism in severe trauma patients: a multicenter double blind randomi … Pending
  2025-522832-16-00 10 Severe trauma
• Use of low doses of interleukin-2 in autism spectrum disorders Pending
  2025-522841-23-00 4 Autism Spectrum disorder ASD
• Upadacitinib in adult patients with erosive mucosal Lichen Planus and Lichen Planopilaris. Pending
  2025-522870-35-00 4 Lichen
• A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy Pending
  2025-522949-22-00 5 Duchenne muscular dystrophy
• Osteogenesis Imperfecta Trial of AGA2115 for ADUlts with COL1A1 and/or COL1A2 GeNetic Variations (IDUN) Pending
  2025-522951-24-00 4 Osteogenesis Imperfecta
• A Study to Learn About the Study Medicine Called PF-08049820 in People With Eczema, an Itchy Skin Rash Pending
  2025-522965-31-00 4 Atopic Dermatitis
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study with an Open-Label Extension to Evaluate the Efficacy and Safety of In … Pending
  2025-523087-20-00 5 Duchenne muscular dystrophy
• Effects of butyrate enemas on postoperative intestinal motility disorders in Hirschsprung’s disease Pending
  2025-523094-42-00 5 Hirschsprung's disease
• KARMA - INtenSive care TreAtmeNT with adjuvant KetAmine and Recovery after Mechanical ventilAtion: a multicenter doubleblind randomized cont … Pending
  2025-523149-80-00 10 Adult patients admitted to the ICU and receiving unplanned invasive me
• A study to learn if fenfluramine hydrochloride is safe and works in people with Rett syndrome Pending
  2025-523157-34-00 5 Rett syndrome
• Study of ASP2957 in Male Patients with X-linked Myotubular Myopathy Who Need Ventilators Pending
  2025-523213-29-00 7 X-linked myotubular myopathy
• A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma. Pending
  2025-523285-25-00 5 Relapsed or Refractory Multiple Myeloma
• Evaluation of MTX-474 in Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc) Pending
  2025-523288-39-00 4 Diffuse Cutaneous Systemic Sclerosis (dcSSc)
• THERIPEX Pending
  2025-523305-15-00 1 IPEX syndrome is a primary immunodeficiency caused by hemizygous mutat

Showing 169–192 of 2,322 trials